JL,
feel free to start your own website
Apologize for not having been more clear. I have (and have had) no intention of starting any website or joining any such effort.
In my few, recent posts I have discussed the idea of informed customers of insurance companies/PBMs communicating their concerns about tier designation (such as mine, Tier 4 (non-preferred brand drug), for CVS Caremark Silvercripts Plan) and any knowledge that such PBM/insurer has (improperly) claimed Vascepa to have a less costly clinical equivalent. Such communications might eventually include links to the NEJM article, Vascepa HCP webpage, Mason presentation, Pleiotropic effects article, etc.
I have already initiated such a conversation with CVS Caremark Silverscripts.
Mindful of another's suggestion that coordination with Amarin might be advisable, I am considering asking IR whether they would prefer that shareholders who happen to be insureds and who desire to communicate with their insurance companies/PBMs about such subjects refrain from doing so. To illustrate the concept, I might give Amarin a sample communication.
I doubt Amarin would want to be in the position of "approving of," "supporting" or "coordinating" such efforts, but they might want the opportunity to request that shareholder-insureds refrain from such contacts.
If I take this further and obtain any information of interest, I will post it.
cmm3rd
Market Data 
Markets 
AI
